MDT-AP-1260
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 72
- os_event
- false
- age_years
- 8
- sex
- F
- new_clusters
- C5
- umap1_2d
- 4.816726999
- umap2_2d
- 4.925083097
- umap1_3d
- 2.32770477
- umap2_3d
- -0.450487657
- umap3_3d
- -2.254533704
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.290
- HEDGEHOG_SIGNALING+0.200
- KRAS_SIGNALING_DN+0.170
- SPERMATOGENESIS+0.100
- DNA_REPAIR+0.050
- MYOGENESIS+0.020
- XENOBIOTIC_METABOLISM+0.020
- OXIDATIVE_PHOSPHORYLATION+0.010
- ESTROGEN_RESPONSE_LATE+0.000
- APICAL_JUNCTION-0.020
Top 10 suppressed
- G2M_CHECKPOINT-0.400
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- E2F_TARGETS-0.390
- IL6_JAK_STAT3_SIGNALING-0.380
- UNFOLDED_PROTEIN_RESPONSE-0.380
- TNFA_SIGNALING_VIA_NFKB-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- INTERFERON_GAMMA_RESPONSE-0.360
- TGF_BETA_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1089 | — | — | 0.925 |
| 2 | SRR1343841 | GTEX | — | 0.919 |
| 3 | TCGA-E9-A245-01A-22R-A16F-07 | — | B | 0.918 |
| 4 | MDT-AP-2026 | Med | Medulloblastoma | 0.915 |
| 5 | SRR1466993 | GTEX | — | 0.910 |
| 6 | SRR1324431 | GTEX | — | 0.909 |
| 7 | SRR1340907 | GTEX | — | 0.908 |
| 8 | MNG700 | — | — | 0.907 |
| 9 | SRR1409282 | GTEX | — | 0.906 |
| 10 | SRR1395834 | GTEX | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |